By translating a deep expertise in growth factor biology, we pioneer and develop novel treatments that aim to resolve fibrosis, repair tissue structure, and restore organ function. We combine our innovative R&D approach with an ambitious corporate strategy to develop a broad clinical pipeline of assets that target two key signaling pathways that are involved in fibrosis: transforming growth factor beta (TGFβ) and hepatocyte growth factor (HGF).

Recent Milestones: start phase 2 study in fibrostenosing Crohn’s disease, start phase 1 in HVs and IPF patients, $100M series C financing round
Upcoming Milestones: Phase 2 results, phase 1 results
Products: 1) gut-restricted ALK5 inhibitor for fibrostenosing Crohn’s disease, 2) lung-restricted ALK5 inhibitor for idiopathic pulmonary fibrosis, 3) MET agonist for fibrotic indications
Investors: EQT, Fidelity, KKR, Canaan, Redmile, Cormorant, Pontifax, Pfizer, Boehringer Ingelheim venture fund, Andera, Walleye, Adbio, Asabys, Omnes, V-Bio
Full Company address & contact details: info@agomab.com.

https://agomab.com/